

# Extraordinary Report

March 24, 2021

(TRANSLATION)

**Note for readers of this English translation**

On March 24, 2021, Chugai Pharmaceutical Co., LTD. (the “Company”) filed its Japanese-language Extraordinary Report (Rinji Houkokusho) (the “Report”) with the Director-General of the Kanto Financial Bureau in Japan in connection with the Company's shareholders' voting results for proposals acted upon at the 110th Annual General Meeting of Shareholders held on March 23, 2021 pursuant to the Financial Instruments and Exchange Act of Japan. This document is an English translation of the Report.

**1. Reason for submitting the Extraordinary Report**

Given that resolutions were made for the proposals at the 110th Annual General Meeting of Shareholders (the “Meeting”) held on March 23, 2021, Chugai Pharmaceutical Co., Ltd (the “Company”) submits this Extraordinary Report under the provisions of Article 24-5, Paragraph 4, of the Financial Instruments and Exchange Act of Japan and Article 19, Paragraph 2, Item 9-2, of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.

**2. Contents of the Extraordinary Report**

(1) Date when the Meeting was held: March 23, 2021

**(2) Matters for resolution**

First Proposal            Appropriation of Surplus

Year-end dividend

JPY 30 per share of common stock of the Company

Second Proposal        Election of Five (5) Directors

Masayuki Oku, Yoichiro Ichimaru, Christoph Franz, William N. Anderson, and James H. Sabry were elected as directors of the Company.

Third Proposal         Election of One (1) Audit & Supervisory Board Member

Yoshiaki Ohashi was elected as Audit & Supervisory Board Member of the Company.

(3) Number of voting rights concerning the indication of "for", "against" or "abstention" for each proposal; Requirements for approving the proposals; and Results of resolutions

Proposal	For	Against	Abstention	Ratio of favorable votes	Results
First Proposal	15,532,506	17,185	6,137	99.85%	Approved
Second Proposal					
Masayuki Oku	15,532,559	17,127	6,137	99.85%	Approved
Yoichiro Ichimaru	15,544,942	4,745	6,137	99.93%	Approved
Christoph Franz	15,479,536	66,788	9,498	99.51%	Approved
William N. Anderson	15,487,625	58,700	9,498	99.56%	Approved
James H. Sabry	15,487,569	58,756	9,498	99.56%	Approved
Third Proposal					
Yoshiaki Ohashi	15,425,176	123,057	320	99.21%	Approved

Notes: Requirements for the approval of each proposal are as follows:

- 1) The resolution for the First Proposal must be adopted by a majority of the votes of the shareholders present at the Meeting, who are entitled to exercise voting rights.
- 2) The resolution for the Second and Third Proposals must be adopted by a majority of the votes of the shareholders present at the Meeting where the number of the voting rights of the shareholders present, amounts to one-third (1/3) or more.

(4) Reason why a portion of the voting rights held by the shareholders present at the Meeting held on March 23, 2021 was not added to the number of voting rights

In terms of Japanese Companies Act, the required majority approval for each proposal was met by the votes exercised prior to the Meeting held on March 23, 2021, as well as the votes exercised by a portion of shareholders present and confirmed by the Company at the Meeting held on March 23, 2021; so that, the voting rights of the shareholders present at the Meeting held on March 23, 2021, untraceable with the final decision of "for", "against" or "abstention" as to each proposal were not tallied.